文献速递浆细胞疾病

多参数流式细胞术评估AL淀粉样变性患者微小残留病

Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis.
PubMed 文献 · Blood Adv · 2020-01-01

该研究采用2管10色多参数流式细胞术,在最低灵敏度1/10^5个有核细胞下评估65例血液学完全缓解的AL淀粉样变性患者的微小残留病(MRD)。36例(55%)检出残留克隆性浆细胞;数据提示MRD阴性可能与治疗后更高的器官缓解概率相关。

要点

  • 血液学完全缓解的AL淀粉样变性患者中55%仍可检出残留克隆性浆细胞。
  • MRD阴性是否改善器官缓解尚需更大规模前瞻性研究验证。

核心结论

  • 数据提示MRD阴性可能与AL淀粉样变性治疗后更高的器官缓解概率相关。

研究设计与样本

  • 采用2管10色多参数流式细胞术,最低灵敏度为1/10^5个有核细胞。
  • 纳入65例血液学完全缓解的AL淀粉样变性患者评估MRD。
  • 试验注册号为NCT00898235。

主要发现

  • 65例患者中36例(55%)骨髓检出残留克隆性浆细胞。

临床怎么用

  • 对血液学完全缓解的AL淀粉样变性患者,可考虑用多参数流式细胞术评估MRD以辅助判断器官缓解概率。
  • MRD阴性者器官缓解概率在数值上更高,但当前证据尚不足以据此改变治疗决策。

局限性

  • 样本量有限(65例),各组比较均未达统计学显著。
  • 作者指出需要更大规模前瞻性研究确定这些改善的临床相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite achieving a hematologic complete response after treatment, many patients with AL amyloidosis do not attain recovery of organ function and/or experience hematologic relapse. A persistent plasma cell clone producing amyloidogenic light chains at levels below the detection threshold of traditional serologic methods is hypothesized to impede organ response in some patients. Assessment of minimal residual disease (MRD) may therefore have clinical importance as a more stringent treatment response tool for patients in a hematologic complete response. We used 2-tube, 10-color combination multiparametric flow cytometry to assess for MRD at a minimum sensitivity of 1 in 105 nucleated cells. Of 65 patients in hematologic complete response, 36 (55%) were found to have a residual clonal plasma cell population in the bone marrow. Comparing the MRD-negative and MRD-positive groups, renal response was observed in 88% vs 64% (P = .06), cardiac response in 75% vs 59% (P = .45), and any organ response in 90% vs 75% (P = .20) of patients. Depth of organ response as measured by the percent decrease in 24-hour proteinuria and brain natriuretic peptide was 96% vs 91% (P = .16) and 55% vs 46% (P = .66), respectively. These data suggest a possible correlation between MRD negativity and higher probability of organ response after treatment in AL amyloidosis. Future prospective studies with a larger cohort are needed to determine the clinical relevance of these improvements. This trial was registered at www.clinicaltrials.gov as #NCT00898235.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Staron A, Burks EJ, Lee JC, et al. Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis. Blood Adv. 2020. PMID: 32130406. doi:10.1182/bloodadvances.2019001331

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。